Celtec Inc.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
Dendritic Cell Cancer Therapy
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2016
Unified Business No.
52464901
Status
Active
Number of Employees
0
Total Paid-in
Capital
22,800,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The founder of Zentai Biotech previously worked at Fountain Biopharma and SynCore Biotechnology under the Microbio Group, and once conducted drug development under the late Harvard University professor Dr. Judah Folkman, the internationally renowned "Father of Angiogenesis," participating in the development of three angiogenesis inhibitor drugs with total annual sales exceeding USD 15 billion. Zentai Biotech specializes in the fields of immunotherapy and immune cell therapy, and has already achieved significant results in the application and development of dendritic cells.
(The content above was translated by AI.)
(The content above was translated by AI.)
